Biomea Fusion

General Information

We are a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. An irreversible small molecule drug is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure and the ability to drive a deeper, more durable response. Leveraging our extensive expertise in irreversible binding chemistry and development, we built our proprietary FUSION System discovery platform to advance a pipeline of novel irreversible small molecule product candidates. Our lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.



Employees: 12
Founded: 2017
Contact Information
Address 726 Main Street Redwood City, California 94063
Phone Number (650) 980-9099
Web Address
View Prospectus: Biomea Fusion
Financial Information
Market Cap $436.32mil
Revenues $0 mil (last 12 months)
Net Income $-5.32 mil (last 12 months)
IPO Profile
Symbol BMEA
Exchange NASDAQ
Shares (millions): 9.0
Price range $17.00 - $17.00
Est. $ Volume $153.0 mil
Manager / Joint Managers J.P. Morgan/ Jefferies/ Piper Sandler
CO-Managers -
Expected To Trade: 4/16/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change